Data as of Apr 17
| +0.01 / +0.93%|
The 1 analysts offering 12-month price forecasts for Ventrus Biosciences Inc have a median target of 2.50, with a high estimate of 2.50 and a low estimate of 2.50. The median estimate represents a +131.48% increase from the last price of 1.08.
The current consensus among 2 polled investment analysts is to Hold stock in Ventrus Biosciences Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.